
Cue Biopharma, Inc.
100
Recent developments for Cue Biopharma include widening Q2 net loss with anticipation of Phase 2 data for CUE-221 in chronic spontaneous urticaria by end of Q3 2026, management appointments, milestone payments, and collaboration revenue improvements.
- Cue Biopharma reported a widened Q2 net loss and anticipates Phase 2 data for CUE-221 in chronic spontaneous urticaria by the end of Q3 2026 [N1].
- The company appointed Ahlers as CFO following IND filing and pipeline progress [N2].
- Cue Biopharma made board changes and was noted among top biotech gainers [N3].
- The company is set to receive a $7.5 million milestone payment [N4].
- Collaboration revenue improved in Q4 and fiscal year 2025 [N5].
- The company reported a Q3 loss and lagged revenue estimates in a prior period [N6].
Cue Biopharma, Inc. develops novel injectable therapeutics engineered to selectively engage and modulate disease-specific T cells via its Immuno-STAT platform. This platform is designed to restore immune balance by selectively targeting disease-relevant T cells, aiming to improve efficacy and reduce off-target effects. The company’s pipeline includes the CUE-400 series for autoimmune diseases (e.g., CUE-401), the CUE-500 series for targeted cell depletion (e.g., CUE-501 licensed to Boehringer Ingelheim), and the CUE-100 series for oncology indications (e.g., CUE-101 and CUE-102 licensed to ImmunoScape). Cue Biopharma has established collaborations and license agreements to advance its pipeline and has regained certain rights previously licensed out. The company is preparing for clinical trials, including an IND filing for CUE-401 in 2026. Financially, the company maintains solid liquidity with cash and equivalents of $57.9 million as of Q3 2026 but continues to report net losses consistent with its clinical-stage status.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies using its proprietary Immuno-STAT platform to selectively modulate disease-specific T cells for autoimmune, inflammatory, and oncology indications. The company’s pipeline includes preclinical and clinical-stage candidates such as CUE-401 for autoimmune diseases, CUE-501 for targeted B cell depletion licensed to Boehringer Ingelheim, and oncology candidates CUE-101 and CUE-102 licensed to ImmunoScape. As of September 30, 2026, Cue Biopharma reported $57.9 million in cash and equivalents, a current ratio of 3.38, and a net loss of $50.0 million for the quarter. Recent developments include IND filing preparations for CUE-401, milestone payments, collaboration revenue improvements, and management appointments. The company faces risks typical of clinical-stage biopharmaceutical firms, including clinical, regulatory, intellectual property, and market risks. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Cue Biopharma’s Immuno-STAT platform represents a novel and differentiated approach to precision immunotherapy, with potential to selectively restore immune balance and target pathogenic cells across autoimmune, inflammatory, and oncology indications. The company’s pipeline includes promising candidates such as CUE-401 nearing IND filing and CUE-501 licensed to a major pharmaceutical partner, which could enable accelerated development and commercialization. Strategic collaborations and milestone payments provide validation and potential near-term value inflection points. The company’s solid liquidity supports ongoing R&D activities and clinical trial preparations.
Cue Biopharma faces typical risks of clinical-stage biopharmaceutical companies, including the possibility of clinical trial failures, regulatory setbacks, and challenges in demonstrating safety and efficacy of novel therapeutics. The company continues to report significant net losses and depends on external financing and collaborations to fund operations. Market risks include stock price volatility, potential Nasdaq delisting risks, and dilution from equity offerings. Intellectual property disputes or failure to meet license obligations could adversely affect operations. The company’s ability to successfully commercialize its pipeline remains uncertain.
Cue Biopharma’s moat derives from its proprietary Immuno-STAT platform, which offers a modular and flexible approach to selectively modulate disease-specific T cells, potentially enabling differentiated therapies with improved efficacy and safety profiles. The company’s exclusive worldwide license from Albert Einstein College of Medicine for core technology patents, combined with strategic collaborations with established pharmaceutical companies such as Boehringer Ingelheim and ImmunoScape, further strengthen its competitive position. The platform’s ability to address multiple autoimmune, inflammatory, and oncology indications through distinct pipeline assets enhances its potential to establish new standards of care. However, as a clinical-stage company, the moat is contingent on successful clinical development and regulatory approvals.
• Clinical and Regulatory Risks: Setbacks in clinical trials or adverse regulatory actions could delay or prevent product approvals, impacting development timelines and business prospects.
• Financial and Market Risks: Continued net losses and dependence on external financing expose the company to liquidity risks and potential dilution. Stock price volatility and Nasdaq listing compliance pose additional market risks.
• Intellectual Property Risks: The company relies on licensed patents and proprietary technology; failure to maintain or enforce intellectual property rights could harm competitive position.
• Operational Risks: Dependence on collaborations and license agreements introduces risks related to partner performance and contractual obligations.
Business trends: Advancement of Immuno-STAT platform pipeline with IND filing preparations and Phase 2 data readouts; strategic collaborations supporting development.
Execution milestones: IND filing for CUE-401; Phase 2 clinical data for CUE-221 in CSU; milestone payments and collaboration revenue growth.
Key risks: Clinical trial and regulatory uncertainties; financial sustainability amid ongoing losses; intellectual property and collaboration dependency risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for autoimmune and inflammatory diseases using its Immuno-STAT platform [S1].
- The Immuno-STAT platform is modular and designed to restore immune balance by selectively modulating disease-relevant T cells, aiming to enhance efficacy and minimize off-target effects [S1].
- The company’s pipeline includes: CUE-400 series targeting autoimmune diseases by inducing regulatory T cells (Tregs) and restoring immune tolerance (e.g., CUE-401); CUE-500 series for targeted cell depletion by redirecting antiviral killer T cells to eliminate pathogenic cells (e.g., CUE-501 licensed to Boehringer Ingelheim); and CUE-100 series for oncology indications (e.g., CUE-101 and CUE-102 licensed to ImmunoScape) [S1].
- CUE-401 is a preclinical bifunctional fusion protein designed to promote immune tolerance by inducing Tregs and reducing pro-inflammatory autoreactive cells, with IND-enabling studies nearing completion and an IND filing planned for Q2 2026 [S1].
- The company has collaborations and license agreements with Boehringer Ingelheim for CUE-501, ImmunoScape for CUE-100 series, and regained rights for CUE-401 from Ono Pharmaceutical [S1].
- Financial snapshot as of September 30, 2026: cash and equivalents of $57.9 million, current assets of $66.7 million, current liabilities of $19.7 million, resulting in a current ratio of 3.38 and cash ratio of 2.94, indicating solid liquidity [S2].
- Net loss for the quarter ended September 30, 2026, was $50.0 million with basic and diluted EPS of -$4.74 per share [S2].
- The company’s recent news highlights include widening Q2 net loss, anticipation of Phase 2 data for CUE-221 in chronic spontaneous urticaria (CSU) by end of Q3 2026, appointment of a new CFO following IND filing and pipeline progress, receipt of milestone payments, and collaboration revenue improvements [N1][N2][N4][N5].
- The company implemented a 1-for-30 reverse stock split in April 2026 and regained compliance with Nasdaq’s minimum bid price requirement in May 2026 [S1].
- Cue Biopharma has a royalty-bearing license agreement with Albert Einstein College of Medicine for its core technology platform, with milestone and royalty payment obligations [S1].
- The company faces risks including clinical trial setbacks, regulatory actions, intellectual property challenges, stock price volatility, potential Nasdaq delisting risks, and limitations on net operating loss utilization [S1][S2].
Generated 2026-11-17
- S1
- S2
- S1 | 2026-03-16 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-08-17 | www.nasdaq.com | Cue Biopharma Q2 Net Loss Widens; Expects Phase 2 Data For CUE-221 In CSU By End Of Q3 2026 | https://www.nasdaq.com/articles/cue-biopharma-q2-net-loss-widens-expects-phase-2-data-cue-221-csu-end-q3-2026
- N2 | 2026-08-04 | www.nasdaq.com | Cue Biopharma Appoints Ahlers As CFO Following IND Filing And Pipeline Progress | https://www.nasdaq.com/articles/cue-biopharma-appoints-ahlers-cfo-following-ind-filing-and-pipeline-progress
- N3 | 2026-06-03 | www.nasdaq.com | Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL | https://www.nasdaq.com/articles/top-biotech-gainers-pmi-advances-artificial-heart-cue-makes-board-changes-cing-despite-crl
- N4 | 2026-04-09 | www.nasdaq.com | Cue Biopharma To Receive $7.5M Milestone Payment | https://www.nasdaq.com/articles/cue-biopharma-receive-75m-milestone-payment
- N5 | 2026-03-17 | www.nasdaq.com | Cue Biopharma Q4 And FY25 Collaboration Revenue Improves | https://www.nasdaq.com/articles/cue-biopharma-q4-and-fy25-collaboration-revenue-improves
- N6 | 2025-11-12 | www.nasdaq.com | Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/cue-biopharma-inc-cue-reports-q3-loss-lags-revenue-estimates
- N7 | 2025-11-07 | www.nasdaq.com | CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/cervomed-inc-crvo-reports-q3-loss-misses-revenue-estimates
- N8 | 2025-11-06 | www.nasdaq.com | Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates | https://www.nasdaq.com/articles/puma-biotech-pbyi-q3-earnings-and-revenues-top-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


